The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region
Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-lin...
Gespeichert in:
Veröffentlicht in: | Advances in therapy 2021-02, Vol.38 (2), p.925-948 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 948 |
---|---|
container_issue | 2 |
container_start_page | 925 |
container_title | Advances in therapy |
container_volume | 38 |
creator | Cheng, Kevin Alhumood, Khaldoon El Shaer, Fayez De Silva, Ranil |
description | Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region. |
doi_str_mv | 10.1007/s12325-020-01582-w |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7889547</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2472111962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</originalsourceid><addsrcrecordid>eNp9kUlLBDEUhIMoOi5_wIP00Utr9qQvggxu4AIuoKeQSSczke5Ek2nFf290VPTiIbxDfa9SvAJgG8E9BKHYzwgTzGqIYQ0Rk7h-XQIjJDmry8PLYAQFRTUm8n4NrOf8CAspmFwFa4QQhpBgI_BwO7PVdexsFV116U1MOrS-q3yo5kW50EFPbW_D_EMfz1IM3lTjWKZOb9XNW2hT7G3-5k-GzlXXdupj2AQrTnfZbn3NDXB3fHQ7Pq3Pr07OxofntaGUz2vaOk0p4YLRiZhwyrGmGGGHGy4h0pJMGmagM4w4yFsnGiQwxbxtC2GQk2QDHCx8n4ZJb1tTsibdqafk-xJRRe3VXyX4mZrGFyWkbBgVxWD3yyDF58Hmuep9NrbrdLBxyApTgRFCDccFxQvUpJhzsu7nGwTVRydq0Ykql1afnajXsrTzO-DPyncJBSALIBcpTG1Sj3FIoRztP9t3Lb2YDw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2472111962</pqid></control><display><type>article</type><title>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Cheng, Kevin ; Alhumood, Khaldoon ; El Shaer, Fayez ; De Silva, Ranil</creator><creatorcontrib>Cheng, Kevin ; Alhumood, Khaldoon ; El Shaer, Fayez ; De Silva, Ranil</creatorcontrib><description>Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-020-01582-w</identifier><identifier>PMID: 33351175</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Angina, Stable - drug therapy ; Cardiology ; Cardiovascular Agents - therapeutic use ; Endocrinology ; Humans ; Internal Medicine ; Medicine ; Medicine & Public Health ; Nicorandil - therapeutic use ; Oncology ; Pharmacology/Toxicology ; Quality of Life ; Review ; Rheumatology ; Syndrome ; Vasodilator Agents - therapeutic use</subject><ispartof>Advances in therapy, 2021-02, Vol.38 (2), p.925-948</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</citedby><cites>FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</cites><orcidid>0000-0002-1031-4017 ; 0000-0003-1107-2117 ; 0000-0003-1262-9474</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-020-01582-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-020-01582-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33351175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Kevin</creatorcontrib><creatorcontrib>Alhumood, Khaldoon</creatorcontrib><creatorcontrib>El Shaer, Fayez</creatorcontrib><creatorcontrib>De Silva, Ranil</creatorcontrib><title>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.</description><subject>Angina, Stable - drug therapy</subject><subject>Cardiology</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nicorandil - therapeutic use</subject><subject>Oncology</subject><subject>Pharmacology/Toxicology</subject><subject>Quality of Life</subject><subject>Review</subject><subject>Rheumatology</subject><subject>Syndrome</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUlLBDEUhIMoOi5_wIP00Utr9qQvggxu4AIuoKeQSSczke5Ek2nFf290VPTiIbxDfa9SvAJgG8E9BKHYzwgTzGqIYQ0Rk7h-XQIjJDmry8PLYAQFRTUm8n4NrOf8CAspmFwFa4QQhpBgI_BwO7PVdexsFV116U1MOrS-q3yo5kW50EFPbW_D_EMfz1IM3lTjWKZOb9XNW2hT7G3-5k-GzlXXdupj2AQrTnfZbn3NDXB3fHQ7Pq3Pr07OxofntaGUz2vaOk0p4YLRiZhwyrGmGGGHGy4h0pJMGmagM4w4yFsnGiQwxbxtC2GQk2QDHCx8n4ZJb1tTsibdqafk-xJRRe3VXyX4mZrGFyWkbBgVxWD3yyDF58Hmuep9NrbrdLBxyApTgRFCDccFxQvUpJhzsu7nGwTVRydq0Ykql1afnajXsrTzO-DPyncJBSALIBcpTG1Sj3FIoRztP9t3Lb2YDw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Cheng, Kevin</creator><creator>Alhumood, Khaldoon</creator><creator>El Shaer, Fayez</creator><creator>De Silva, Ranil</creator><general>Springer Healthcare</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1031-4017</orcidid><orcidid>https://orcid.org/0000-0003-1107-2117</orcidid><orcidid>https://orcid.org/0000-0003-1262-9474</orcidid></search><sort><creationdate>20210201</creationdate><title>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</title><author>Cheng, Kevin ; Alhumood, Khaldoon ; El Shaer, Fayez ; De Silva, Ranil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-4dfa4436754b7b6462a4212f296801a83b95c0fc53f06df79172426ddf29c1f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Angina, Stable - drug therapy</topic><topic>Cardiology</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nicorandil - therapeutic use</topic><topic>Oncology</topic><topic>Pharmacology/Toxicology</topic><topic>Quality of Life</topic><topic>Review</topic><topic>Rheumatology</topic><topic>Syndrome</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Kevin</creatorcontrib><creatorcontrib>Alhumood, Khaldoon</creatorcontrib><creatorcontrib>El Shaer, Fayez</creatorcontrib><creatorcontrib>De Silva, Ranil</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Kevin</au><au>Alhumood, Khaldoon</au><au>El Shaer, Fayez</au><au>De Silva, Ranil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>38</volume><issue>2</issue><spage>925</spage><epage>948</epage><pages>925-948</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Chronic coronary syndromes (CCS) and stable angina are a growing clinical burden worldwide. This is of particular concern in the Gulf region given its high prevalence of cardiovascular risk factors, especially diabetes mellitus and smoking. Despite recommendations on the use of first- and second-line anti-anginal medication, management challenges remain. Current guidelines for pharmacologic treatment are not determined by the range of pathophysiological mechanisms of ischaemia and consequent angina, which may occur either in isolation or co-exist. In this article, we highlight the need to improve knowledge of the epidemiology of chronic coronary syndromes in the Middle East and Gulf region, and the need for studies of stratified pharmacologic approaches to improve symptomatic angina and quality of life in the large and growing number of patients with coronary artery disease from this region. We discuss the role of nicorandil, currently recommended as a second-line anti-anginal drug in CCS patients, and suggest that this may be a particularly useful add-on therapy for patients in the Gulf region.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>33351175</pmid><doi>10.1007/s12325-020-01582-w</doi><tpages>24</tpages><orcidid>https://orcid.org/0000-0002-1031-4017</orcidid><orcidid>https://orcid.org/0000-0003-1107-2117</orcidid><orcidid>https://orcid.org/0000-0003-1262-9474</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0741-238X |
ispartof | Advances in therapy, 2021-02, Vol.38 (2), p.925-948 |
issn | 0741-238X 1865-8652 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7889547 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Angina, Stable - drug therapy Cardiology Cardiovascular Agents - therapeutic use Endocrinology Humans Internal Medicine Medicine Medicine & Public Health Nicorandil - therapeutic use Oncology Pharmacology/Toxicology Quality of Life Review Rheumatology Syndrome Vasodilator Agents - therapeutic use |
title | The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A13%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Nicorandil%20in%20the%20Management%20of%20Chronic%20Coronary%20Syndromes%20in%20the%20Gulf%20Region&rft.jtitle=Advances%20in%20therapy&rft.au=Cheng,%20Kevin&rft.date=2021-02-01&rft.volume=38&rft.issue=2&rft.spage=925&rft.epage=948&rft.pages=925-948&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-020-01582-w&rft_dat=%3Cproquest_pubme%3E2472111962%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2472111962&rft_id=info:pmid/33351175&rfr_iscdi=true |